A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Non-Hodgkin Lymphoma
DRUG: SC Mosunetuzumab|DRUG: IV Glofitamab|DRUG: Iberdomide|DRUG: Golcadomide|DRUG: Obinutuzumab|DRUG: Tocilizumab
Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation], Until 90 days after the final dose of study treatment|Percentage of participants with adverse events [all cohorts], Until 90 days after the final dose of study treatment|Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion], Up to 2 years after start of primary study treatment|Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation], Until 90 days after the final dose of study treatment
Best CR rate, defined as the proportion of participants whose best overall response is a CR during the study, as determined by the investigator using Lugano 2014 criteria [all cohorts], Up to 1 year after primary study treatment|Best ORR (CR or PR at any time) on study as determined by the investigator using Lugano 2014 criteria [dose escalation], Up to 2 years after primary study treatment|Duration of response (DOR) as determined by the investigator using Lugano 2014 criteria [all cohorts], Up to 2 years after primary study treatment|Progression-free survival (PFS) as determined by the investigator using Lugano 2014 criteria [dose expansion], Up to 2 years after primary study treatment|Event-free survival (EFS) as determined by the investigator using Lugano 2014 criteria [dose expansion], Up to 2 years after primary study treatment|Overall survival (OS) [dose expansion], Up to 2 years after primary study treatment|Percentage of participants with adverse events [dose expansion], Until 90 days after the final dose of study treatment|Serum concentration of subcutaneous (SC) mosunetuzumab [all cohorts], Up to 2 years after primary study treatment|Serum concentration of intravenous (IV) glofitamab [all cohorts], Up to 2 years after primary study treatment|Serum concentration of CC-220 and CC-99282 (CELMoDs) [all cohorts], Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2)|Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose expansion], Until 90 days after the final dose of study treatment
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.